Solvay Moves Ahead With Cell-Derived Flu Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Solvay will design a clinical trial program for its cell-derived influenza vaccine with guidance from FDA, following submission of a drug master file
You may also be interested in...
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Flu Vaccine Manufacturing With Canine Kidney Cells To Be Discussed By Committee In November
FDA's vaccines advisory committee will discuss Madin-Darby canine kidney cells for flu vaccine manufacturing Nov. 16. Solvay submitted a drug master file for a canine cell-based influenza vaccine in June.
Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.